Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 14 (12), 697-710

Proton-pump Inhibitors: Understanding the Complications and Risks

Affiliations
Review

Proton-pump Inhibitors: Understanding the Complications and Risks

Peter Malfertheiner et al. Nat Rev Gastroenterol Hepatol.

Abstract

Proton-pump inhibitors (PPIs) are the most effective therapy for the full spectrum of gastric-acid-related diseases. However, in the past decade, a steadily increasing list of complications following long-term use of PPIs has been reported. Their potent acid-suppressive action induces several structural and functional changes within the gastric mucosa, including fundic gland polyps, enterochromaffin-like cell hyperplasia and hypergastrinaemia, which can be exaggerated in the presence of Helicobacter pylori infection. As discussed in this Review, most associations of PPIs with severe adverse events are not based on sufficient evidence because of confounding factors and a lack of plausible mechanisms. Thus, a causal relationship remains unproven in most associations, and further studies are needed. Awareness of PPI-associated risks should not lead to anxiety in patients but rather should induce the physician to consider the appropriate dosing and duration of PPI therapy, including long-term monitoring strategies in selected groups of patients because of their individual comorbidities and risk factors.

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles

References

    1. Circ Res. 2016 Jun 10;118(12 ):e36-42 - PubMed
    1. Am J Gastroenterol. 2011 Jul;106(7):1209-18; quiz 1219 - PubMed
    1. Pharmacogenomics J. 2015 Feb;15(1):20-5 - PubMed
    1. Dtsch Med Wochenschr. 2010 Nov;135(44):2193-8 - PubMed
    1. J Bone Miner Res. 2010 Oct;25(10):2205-11 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback